OTC ZOVIRAX ADVISORY COMMITTEE REVIEW
This article was originally published in The Tan Sheet
Executive Summary
OTC ZOVIRAX ADVISORY COMMITTEE REVIEW is now expected to take place late this year or the beginning of 1995 in order to give burroughs Wellcome time to submit data that addresses issues raised at FDA's public hearing on May 19. Burroughs Wellcome's NDA to support OTC marketing of Zovirax (acyclovir) to treat recurrent genital herpes was tentatively set to be reviewed by FDA's Nonprescription Drugs and Antiviral Drugs Advisory Committees on July 28.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning